Close Menu

antibodies

The Swedish company will use the funds to grow its pipeline of antibodies to treat metastatic cancer and other diseases with the help of its Abiprot platform.

The company is beginning a multi-site Phase II trial designed to establish that its approach can identify patients who will respond to immuno-oncology drugs.

The firm also aims to commercialize a new version of its PraediCare Dx platform, which will directly detect heterodimer protein complexes on a tumor cell's surface.